Press releases

April 10, 2018 Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing
- Data presented at annual American College of Medical Genetics meeting - Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company's data being presented this week at the American College of Medical Genetics (ACMG) annual meeting in Charlotte, NC . Healthy individuals are increasingly seeking genetic testing to identify their personal risks for inherited conditions such as cancer and cardiovascular disease. An analysis of 1,300 patients tested with a diagnostic-grade genetic screening panel designed for healthy adults found clinically actionable results in 16 percent of patients, predominantly in genes associated with an elevated risk
Read more
March 28, 2018 Invitae Announces Pricing of Public Offering of Common Stock
Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae . The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million . The offering is expected to close on or about April 2, 2018 , subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,666,666 shares of its common stock at the public offering price, less underwriting discounts and commissions. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as the lead manager for the offering. A shelf registration statement relating to the
Read more
March 26, 2018 Invitae Announces Proposed Public Offering of Common Stock
Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae . In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as the lead manager for the offering. A shelf registration statement relating to the shares was filed with the Securities and Exchange
Read more
March 22, 2018 Invitae expands network of patients in rare and ultra-rare diseases
- No Stomach For Cancer among five advocacy groups establishing registry networks to connect patients, clinicians and researchers - I nvitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced an expansion of its network of rare and ultra-rare patient registries in its Patient Insights Network TM (PIN) program to include five additional collaborations with leading advocacy groups across a variety of genetic conditions. The programs are designed to empower patients to be active participants in their networks and further expand Invitae's work to connect patients with rare genetic disorders to research, clinical trials and information on managing their condition. The first PIN to launch is led by No Stomach For Cancer , a leading research and advocacy organization focused on stomach cancer. Known as the Global Gastric Cancer Registry , the program enables patients, advocates, clinicians and researchers to share and access deidentified
Read more
March 16, 2018 Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information
- Combining germline and somatic information provides more comprehensive view from diagnosis through treatment - - Detailed genomic characterization of tumors rapidly enhancing drug development through biomarker-driven clinical trials - Invitae Corporation (NYSE: NVTA) and KEW, Inc. today announced a collaboration to develop comprehensive genomic profiling solutions for sequencing tumor DNA on Invitae's next generation sequencing (NGS) platform. By adding KEW's somatic mutation detection capabilities to Invitae's extensive portfolio of diagnostic genetic testing panels for hereditary cancers, Invitae will be able to help clinicians guide their patients from initial cancer diagnosis through treatment and monitoring. The genetics of both a patient and tumor play an important role in making cancer treatment decisions and informing drug development. Germline testing from Invitae assesses inherited genetic changes that increase the risk of developing certain cancers. Somatic testing from
Read more
February 27, 2018 Invitae expands existing credit facility to provide up to $40.0 million in available growth capital
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has reached an agreement with Oxford Finance, LLC to expand its existing loan and security agreement by $20.0 million , bringing the total remaining capital available under the agreement to $40.0 million . This increase in net borrowing ability provides additional financial flexibility in 2018 as Invitae seeks to grow the size and scope of its genome network. Invitae received gross proceeds of $40.0 million from the first tranche of the credit facility upon closing in March 2017 and currently has an additional $20.0 million in capital available at its discretion. The amendment to the agreement provides an additional $20.0 million that may be funded at Invitae's option during the second quarter 2018. The loan matures in March 2022 . The Company's obligations under the Loan and Security Agreement are subject to quarterly covenants to achieve certain volume and revenue
Read more
February 26, 2018 Invitae to present at the Cowen and Company 38th Annual Health Care Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , chief executive officer of Invitae , will present at the Cowen and Company 38th Annual Health Care Conference  in Boston on Monday, March 12, 2018 at 11:20 a.m. Eastern / 8:20 a.m. Pacific in Boston, Massachusetts . A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is bringing comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. As one of the fastest growing genetic information company, Invitae is advancing the broad potential of genetics, helping to expand its use across the healthcare continuum. The company provides genetic
Read more
February 12, 2018 Invitae reports over 150% volume and over 170% revenue growth for 2017
- Annual test volume exceeds high end of guidance - - Robust test volume and revenue growth expected to continue in 2018 and beyond - - Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific -   Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 . "Over the past year, we have made significant strategic investments that we believe uniquely position our company to deliver affordable, high-quality, comprehensive genetic information and empower individuals to do more with that information," commented Sean George , chief executive officer of Invitae . "Our continued triple-digit volume and revenue growth demonstrates the power of our approach. Our cost structure, scalability and reputation has made us the fastest-growing genetic information company in hereditary cancer, and we are now leveraging that
Read more
January 31, 2018 Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , chief executive officer of Invitae , will participate in two upcoming investor conferences being held in New York City . Sean George will present at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 10:00 a.m. Eastern / 7:00 a.m. Pacific. Additionally, Sean George will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 10:30 a.m. Eastern / 7:30 a.m. Pacific. The live webcasts of both conference presentations may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusions of the presentations and will be archived on the company's website. About Invitae Invitae Corporation's ( NYSE: NVTA ) mission is to bring comprehensive genetic information into mainstream
Read more
January 29, 2018 Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2017 financial results on Monday, February 12, 2018 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 1395729. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to ir@invitae.com . The live webcast of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the
Read more
January 8, 2018 Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018
- 127% increase in annual test volume exceeds high end of projected range - -136% increase in full-year 2017 revenue in line with guidance - - Anticipates continued, robust test volume and revenue growth in 2018 on strength of newly expanded business - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include: 127% year-over-year growth in volume for the base business, excluding acquisitions, to more than 134,000 samples accessioned compared to approximately 59,000 in 2016. The results exceeded the high end of the company's previously increased projected range of 120,000-130,000 samples. 136% growth in revenue in the base business to approximately $59 million, excluding acquisitions. Results were within the company's $55-$65 million revenue guidance.
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 5.68 +0.09 +1.61% Volume: 378,197 20 minute delay April 24, 2018

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com